Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, monoclonal antibodies | 5433 | 2375952-29-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
EBANGA (ansuvimab-zykl) is a Zaire ebolavirus (EBOV) glycoprotein 1 (GP1)-directed recombinant, human IgG1kappa monoclonal antibody that binds to the glycan cap and inner chalice of the EBOV GP1 subunit. The epitope to which it binds is located within the receptor binding domain of EBOV consisting of amino acids LEIKKPDGS (GP residues 111–119).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 21, 2020 | FDA | RIDGEBACK BIOTHERAPEUTICS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | J06BD04 | ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| FDA MoA | N0000194037 | Zaire Ebolavirus Glycoprotein-directed Antibody Interactions |
| FDA EPC | N0000194038 | Zaire Ebolavirus Glycoprotein-directed Antibody |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ebola virus disease | indication | 37109004 | DOID:4325 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Envelope glycoprotein | Glycoprotein | ANTIBODY BINDING | Kd | 9.70 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D11875 | KEGG_DRUG |
| TG8IQ19NG2 | UNII |
| C5432324 | UMLSCUI |
| CHEBI:757877 | CHEBI |
| CHEMBL4594388 | ChEMBL_ID |
| DB16385 | DRUGBANK_ID |
| 11568 | INN_ID |
| C000711947 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1149150009 | SNOMEDCT_US |
| 1149244009 | SNOMEDCT_US |
| 4043837 | VANDF |
| 4043838 | VANDF |
| 018606 | NDDF |
| 2472151 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ebanga | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71655-578 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 400 mg | INTRAVENOUS | BLA | 28 sections |